<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03402295</url>
  </required_header>
  <id_info>
    <org_study_id>GBRAM003r</org_study_id>
    <nct_id>NCT03402295</nct_id>
  </id_info>
  <brief_title>Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation</brief_title>
  <acronym>GBRAM003r</acronym>
  <official_title>Superiority of the Triple Combinations of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in Patients With Newly Diagnose Multiple Myeloma, Eligible for Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Estudos Multicentricos em Onco-Hematologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Estudos Multicentricos em Onco-Hematologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared two main different induction protocols used to treat myeloma eligible
      patients in Brazil. VCD against CTD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim was observe response rate after 4 induction cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 15, 2009</start_date>
  <completion_date type="Actual">October 15, 2017</completion_date>
  <primary_completion_date type="Actual">June 15, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Retrospectively compared two different groups of treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate better than very good partial response after 4 induction cycles</measure>
    <time_frame>Response rate after induction phase - at the end of cycle 4- (28 days each cycle)- time frame trough study completion</time_frame>
    <description>The primary outcome is to observe the difference response rate between VCD and CTD induction myeloma elegible patient</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Effects of Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Vcd- (Bortezomibe, cyclophosphamide and dexamethasone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention - Bortezomib 1.3mg/m2 Intra venous or Subcutaneous once a week (D1-8-15-22) 35days cycle Intervention- Dexamethasone 40mg once a week for four weeks orally or Intravenously- total dose per cycle was 160mg.
Intervention- Cyclophosphamide 900-2000mg- intravenously or orally- total dose monthly Total of four cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ctd- Cyclophosphamide, thalidomide and dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention- Cyclophosphamide 900-2000mg intravenously or orally total dose monthly Intervention- Thalidomide 100-200mg orally- daily dose Intervention -Dexamethasone 40mg once a week for four weeks each month- total dose per cycle was 160mg Total of four cycles (cycles of 28 each one)
28 days each cycles- total of four cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib, cyclophosphamide, thalidomide, dexamethasone</intervention_name>
    <description>Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)</description>
    <arm_group_label>Vcd- (Bortezomibe, cyclophosphamide and dexamethasone)</arm_group_label>
    <arm_group_label>Ctd- Cyclophosphamide, thalidomide and dexamethasone</arm_group_label>
    <other_name>Velcade, genuxal, decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  multiple myeloma newly diagnose elegible to autologous transplantation Patients
             submitted to ctd or vcd Myeloma patients newly diagnose &gt;18yo

        Exclusion Criteria:

          -  other chemotherapy induction protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edvan Cusoe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo de Estudos Multicentricos em Onco-Hematologia</investigator_affiliation>
    <investigator_full_name>Vania TM Hungria</investigator_full_name>
    <investigator_title>Assintant Professor of Hematology oncology- Santa Casa de Sao Paulo Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

